Inside the Structural Reforms That Made IU Indianapolis a Translational Overachiever
How a resource-constrained university built a top-15 translation engine — and what other institutions can learn from it.
Every university on this list represents the highest tier of U.S. biomedical research. We ranked 243 research universities across the United States on their ability to translate scientific discovery into real-world healthcare solutions, evaluated on 25 indicators across three core domains.
Emory University ranks 11th among universities in the Cure Innovation Index. Located in Atlanta, Georgia, Emory places seventh nationally in research capabilities and fourth in entrepreneurial readiness.
Learn More
The University of Pittsburgh ranks 12th among 243 universities in the Cure Innovation Index. Located in Pittsburgh, Pennsylvania, the university performs consistently across all three domains, placing in the upper tier in Research Capabilities and Market Translation, and among the top-ranked universities in Entrepreneurial Readiness.
Learn More
Icahn School of Medicine at Mount Sinai, located in New York, New York, ranks 13th among universities in the Cure Innovation Index. The school places 12th in Research Capabilities and 13th in Market Translation, with a profile balanced between discovery and translation.
Learn More
Cornell University ranks 14th among universities in the Cure Innovation Index, with its main campus in Ithaca, New York. The university places 13th in Entrepreneurial Readiness and 14th in Market Translation, with Research Capabilities ranking 20th.
Learn More
The University of Michigan, Ann Arbor ranks 15th among universities in the Cure Innovation Index, placing in the upper tier across all three measured domains. Located in Ann Arbor, Michigan, it is the state's flagship public university, with Research Capabilities and Market Translation each among the top-ranked in the index and Entrepreneurial Readiness close behind.
Learn More
Columbia University ranks 16th among universities in the Cure Innovation Index. Located in New York, New York, Columbia places in the upper tier across all three evaluated domains: Research Capabilities, Market Translation, and Entrepreneurial Readiness.
Learn More
Northwestern University ranks 17th among 243 universities in the Cure Innovation Index. Located in Evanston, Illinois, the university performs in the upper tier across all three domains, with Market Translation its strongest at 12th.
Learn More
University of North Carolina at Chapel Hill ranks 18th among universities in the Cure Innovation Index. Based in Chapel Hill, North Carolina, the university places in the upper tier across all three assessed domains, with particularly strong standing in Entrepreneurial Readiness, where it ranks 14th.
Learn More
The University of Washington, Seattle ranks 19th among universities in the Cure Innovation Index. The university performs well across all three domains, with Research Capabilities and Market Translation placing it among the top-ranked universities in the U.S., while Entrepreneurial Readiness is also above average.
Learn More
University of Texas Southwestern Medical Center ranks 20th among universities in the Cure Innovation Index, based in Dallas, Texas. Research Capabilities rank 19th, with the institution leaning toward discovery in its overall profile.
Learn More

From a pool of more than 6,000 institutions, the top 303 were ranked using two dozen indicators — from scientific foundation and lab infrastructure to patents, products, and partnerships — drawn from more than a dozen federal and commercial databases, an original audit of all institutions, and surveys of more than 3,300+ scientists, industry leaders, and biomedical experts.
Innovation isn't a single moment — it's an entire ecosystem. The Index evaluates institutions across two dozen indicators, grouped in three core domains that reveal the full picture of what it takes to turn groundbreaking science into real-world impact.
How a resource-constrained university built a top-15 translation engine — and what other institutions can learn from it.
With 27 institutions ranked among the country’s top biomedical innovators, New York’s research cluster spans the entire state, and outperforms nearly every other in the country.

As NIH funding shrinks and industry pulls back from early-stage science, universities are rethinking how discoveries move from the lab to the market.
The Bayh-Dole Act turned federally funded research into a commercialization pipeline that built American biotech. Forty-five years later, that pipeline faces a new set of political and financial pressures that could reshape how it works.
